You just read:

Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)

News provided by

Innovent Biologics, Inc.

Nov 27, 2019, 23:10 ET